Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Overview of Fertility Preservation Strategies in Breast Cancer Care

June 28th 2023

Key opinion leaders on breast cancer management provide a broad overview of fertility preservation strategies available to patients.

Investigation of Pembrolizumab De-Escalation After pCR Aims to Challenge SOC in Early-Stage TNBC

June 27th 2023

Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.

Unmet Needs in Early-Stage HR+/HER2- Breast Cancer

June 27th 2023

Experts on HR+/HER2- breast cancer discuss unmet needs in the early-stage setting.

Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer

June 27th 2023

A panel of expert oncologists review standard-of-care treatment approaches for HR+/HER2- early breast cancer and genetic testing practices when utilizing PARP inhibitors.

Combinación de Ribociclib y Terapia Endocrina en Pacientes con Cáncer de Mama Temprano, Positivo a Receptores Hormonales y Negativo a HER2

June 26th 2023

Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.

FDA Approves Iopromide Injection for Contrast-Enhanced Mammography

June 26th 2023

The FDA has approved the first and only iodine-based contrast agent iopromide-300, -370 injection for intra-arterial and intravenous contrast-enhanced mammography.

SONIA Trial Suggests Second-line Use May Be Optimal for CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

June 24th 2023

The second line may be the optimal setting for patients with HR-positive, HER2-negative advanced breast cancer to receive CDK4/6 inhibitors plus an aromatase inhibitor followed by fulvestrant.

Sacituzumab Govitecan Approaches EU Approval for Pretreated HR+ Metastatic Breast Cancer

June 23rd 2023

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan-hziy monotherapy in select patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr Hamilton on the Investigation of HER3-DXd in ER+ Breast Cancer and TNBC

June 23rd 2023

Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.

Dr Pistilli on Understanding Dynamic HER2 Expression in Metastatic Breast Cancer

June 22nd 2023

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.

Addressing Chemotherapy-Induced Menopause in Patients With Breast Cancer

June 21st 2023

Focused discussion on the incidence of chemotherapy-induced menopause in patients receiving treatment for their breast cancer.

Prevalence of Premenopausal Patients With Breast Cancer

June 21st 2023

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the subset of patients with breast cancer who are premenopausal and how that impacts their approach to disease management.

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

June 19th 2023

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

Dr Vidula on the Evaluation of Talazoparib in BRCA1/2-Mutated Metastatic Breast Cancer

June 19th 2023

Neelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

June 19th 2023

Closing out her discussion on HER2+ metastatic breast cancer, expert oncologist Virginia Kaklamani, MD, DSc, highlights ongoing unmet needs future directions in care.

Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

June 19th 2023

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.

Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast Cancer

June 15th 2023

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches.

Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

June 15th 2023

The addition of gedatolisib to palbociclib and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients with estrogen receptor-positive, HER2-negative advanced breast cancer.

Dr Goel on the Preliminary Efficacy of Tinengotinib Monotherapy in Advanced Solid Tumors

June 13th 2023

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

FDA Grants Priority Review to Capivasertib Plus Fulvestrant in Advanced HR+ Breast Cancer

June 12th 2023

The FDA has accepted and granted priority review designation to the new drug application for the combination of capivasertib and fulvestrant for the treatment of patients with hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer following recurrence or progression on or after endocrine-based therapy.